Breast cancer cells contain several types of hormone receptors for estrogen and/or progesterone that contribute to the growth and function of breast cells.
‘Targeting cell cycle regulating proteins which exhibit tumor-suppressive effects of ER β can help develop new therapy for triple negative breast cancer. ’
Triple negative breast cancer (TNBC), which occurs in 15 percent of diagnosed breast cancers, is an aggressive cancer type defined by the absence of specific receptor proteins that bind the hormones estrogen and progesterone that are present on normal breast cells. The absence of these receptors makes these cancers resistant to targeted hormone treatment, which is commonly used in other breast cancers.
Despite advances in treatment methods, patients with TNBC have a poor prognosis because the cancer is more likely to spread to other organs. In the study, researchers at the Mayo Clinic in Minnesota aimed to better understand and characterize the molecular signaling pathways in these cells in order to identify better treatments.
The researchers found that the growth of TNB cells that lacked estrogen receptor alpha (ER ɑ) in the lab could be significantly slowed by treatment with estrogen or estrogen-like chemicals if the cells presented a second estrogen receptor, ER β.
They also tested this approach in a mouse model which had TNB cells grafted to it, and found that estrogen could prevent tumor growth and in some cases even cause tumor regression if the cells expressed ER.
Importantly, further analysis found that the effects of estrogen on ER were in part due to proteins called cyclin-dependent kinases (CDKs) that control when and how cells divide.
"Our data suggest that the tumor-suppressive effects of ER β in triple negative breast cancer are partly controlled by cell cycle regulating proteins suggesting that targeting these proteins may lead to potentially new and effective therapies for triple negative breast cancer," said Dr. Hawse.
The researchers also note that other studies have observed that patients with TNBC who lack ER ɑ but have ER β have not only an increased survival rate but are also more likely to become cancer-free, supporting the notion that drugs designed specifically to activate ER β, such as estrogen, may provide therapeutic benefits in these patients.